Ribociclib in the neoadjuvant setting was studied in the CORALLEEN Phase II trial with 106 postmenopausal HR+/HER2- early-stage breast cancer patients, mostly luminal B. The primary endpoint was downstaging the risk of recurrence. Here, ERBB2 is linked to breast carcinoma.